BioSpace News Archive

Drug Development

HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023

HOOKIPA Pharma Inc. presented updated data from its ongoing Phase 2 trial of HB-200 in combination with pembrolizumab in patients with recurrent/metastatic Human Papillomavirus 16-positive head and neck cancer.

October 22, 2023
·
11 min read
Drug Development

Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC

Arvinas, Inc. announced the presentation of interim data from the Company’s Phase 1/2 clinical trial for bavdegalutamide, a novel PROTAC® protein degrader targeting the androgen receptor, in a poster session at the European Society for Medical Oncology Congress being held in Madrid from October 20 – 24, 2023.

October 22, 2023
·
11 min read
Drug Development

TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial

Seagen Inc. and Genmab A/S announced results from the Phase 3 innovaTV 301 randomized global trial, which showed treatment with TIVDAK demonstrated a statistically significant and clinically meaningful 30% reduction in the risk of death in recurrent or metastatic cervical cancer patients with disease progression on or after first-line therapy, compared with chemotherapy.

October 22, 2023
·
19 min read
Drug Development

Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)

Regeneron Pharmaceuticals, Inc. and Sanofi announced that positive results from a Phase 3 trial evaluating the investigational use of Dupixent® showed consistent efficacy and safety for up to one year in children aged 1 to 11 years with eosinophilic esophagitis.

October 22, 2023
·
23 min read
Drug Development

Press Release: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)

Positive results from a Phase 3 trial demonstrated the efficacy and safety profile of Dupixent® for up to one year in children aged 1 to 11 years with eosinophilic esophagitis was consistent.

October 22, 2023
·
16 min read